Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic disease that manifests as syncope or sudden death during high adrenergic tone in the absence of structural heart defects. It is primarily caused by mutations in the cardiac ryanodine receptor (RyR2). The mechanism by which these mutations cause arrhythmia remains controversial, with discrepant findings related to the role of the RyR2 binding protein FKBP12.6. The purpose of this study was to characterize a novel RyR2 mutation identified in a kindred with clinically diagnosed CPVT. Single-strand conformational polymorphism analysis and direct DNA sequencing were used to screen the RyR2 gene for mutations. Site-directed mutagenesis was employed to introduce the mutation into the mouse RyR2 cDNA. The impact of the mutation on the interaction between RyR2 and a 12.6 kDa FK506 binding protein (FKBP12.6) was determined by immunoprecipitation and immunoblotting and its effect on RyR2 function was characterized by single cell Ca(2+) imaging and [(3)H]ryanodine binding. A novel CPVT mutation, E189D, was identified. The E189D mutation does not alter the affinity of the channel for FKBP12.6, but it increases the propensity for store-overload-induced Ca(2+) release (SOICR). Furthermore, the E189D mutation enhances the basal channel activity of RyR2 and its sensitivity to activation by caffeine. The E189D RyR2 mutation is causative for CPVT and functionally increases the propensity for SOICR without altering the affinity for FKBP12.6. These observations strengthen the notion that enhanced SOICR, but not altered FKBP12.6 binding, is a common mechanism by which RyR2 mutations cause arrhythmias.
Jiang
Dawei
D
Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada.
Jones
Peter P
PP
Davis
Darryl R
DR
Gow
Robert
R
Green
Martin S
MS
Birnie
David H
DH
Chen
S R Wayne
SR
Gollob
Michael H
MH
D000328:Adult; D000595:Amino Acid Sequence; D000818:Animals; D015153:Blotting, Western; D002110:Caffeine / Q000494:pharmacology; D020013:Calcium Signaling / Q000187:drug effects / Q000235:genetics*; D002460:Cell Line; D002648:Child; D004252:DNA Mutational Analysis; D015716:Electrocardiography, Ambulatory; D005080:Exercise Test; D005260:Female; D020022:Genetic Predisposition to Disease; D040941:Heredity; D006801:Humans; D047468:Immunoprecipitation; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D010375:Pedigree; D010641:Phenotype; D011485:Protein Binding; D012433:Ryanodine / Q000378:metabolism; D019837:Ryanodine Receptor Calcium Release Channel / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism; D022021:Tacrolimus Binding Proteins / Q000378:metabolism; D014162:Transfection; D000098850:Polymorphic Catecholaminergic Ventricular Tachycardia
D019837:Ryanodine Receptor Calcium Release Channel; D012433:Ryanodine; D002110:Caffeine; D022021:Tacrolimus Binding Proteins; C403484:tacrolimus binding protein 1B